Key result
Urinary adiponectin levels were similar in peri- and postmenopausal women with and without metabolic syndrome (2.6 vs. 2.3 ng/mL, P = 0.55), providing no diagnostic value for screening.
Why the study?
To evaluate the association between urinary adiponectin and metabolic syndrome in peri- and postmenopausal women and its potential application as a noninvasive screening tool.
Does urinary adiponectin measurement accurately screen for metabolic syndrome in peri- and postmenopausal women?
Cross-Sectional (n=290)
No
Does urinary adiponectin measurement accurately screen for metabolic syndrome in peri- and postmenopausal women?
Absolute Event Rate: 2.6% vs 2.3%
p-value: p=0.55
Urinary adiponectin is not a useful noninvasive screening biomarker for metabolic syndrome in peri- and postmenopausal women.
Urinary adiponectin lacks screening utility for metabolic syndrome in peri- and postmenopausal women; leaves open its value in other cohorts or with longitudinal designs.
OBJECTIVES: To find the association between urinary adiponectin and metabolic syndrome (MetS) in peri- and postmenopausal women and its potential application as a noninvasive screening for MetS. METHODS: A cross-sectional study was conducted in healthy peri- and postmenopausal women (defined by STRAW + 10 staging) aged at least 40 years who attended annual check-ups or menopause clinics were recruited. Baseline demographic data, MENQOL, anthropometric measurements, blood pressure, laboratory (FBS, total cholesterol, HDL-C, LDL-C, TG), and urinary adiponectin were collected. The MetS was diagnosed according to JIS 2009. RESULTS: 290 peri- and postmenopausal women had participated. The prevalence of Mets among our participants was 18%. Urinary adiponectin levels were similar in peri- and postmenopausal women with and without MetS (2.6 ± 2.2 vs. 2.3 ± 1.9 ng/mL, respectively, P = 0.55). Urinary adiponectin provides no diagnostic value for MetS (AUC = 0.516). CONCLUSIONS: Urinary adiponectin has no role in screening and diagnosing MetS in peri- and postmenopausal women. The quest toward noninvasive screening for MetS is still going on.
No takes yet. Share an insight, caveat, or question.
Vichinsartvichai et al. (2022) conducted a cross-sectional in Metabolic Syndrome (n=290). Urinary adiponectin vs. No metabolic syndrome was evaluated on Urinary adiponectin levels (p=0.55). Urinary adiponectin levels were similar in peri- and postmenopausal women with and without metabolic syndrome (2.6 vs. 2.3 ng/mL, P = 0.55), providing no diagnostic value for screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: